Noubar Afeyan Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the sale, the director now directly owns 2,284,015 shares of the company’s stock, valued at $290,572,388.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Noubar Afeyan also recently made the following trade(s):

• On Tuesday, June 11th, Noubar Afeyan sold 202,832 shares of Moderna stock. The shares were sold at an average price of $148.34, for a total value of $30,088,098.88.
• On Wednesday, June 5th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $151.25, for a total value of $2,268,750.00.
• On Wednesday, May 29th, Noubar Afeyan sold 20,000 shares of Moderna stock. The stock was sold at an average price of $145.08, for a total value of $2,901,600.00.
• On Wednesday, May 22nd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $157.57, for a total transaction of $2,363,550.00.
• On Wednesday, May 15th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $127.32, for a total transaction of $1,909,800.00.
• On Wednesday, May 8th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.68, for a total value of $1,825,200.00.
• On Wednesday, May 1st, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00.
• On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.32, for a total value of $1,624,800.00.
• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $107.12, for a total transaction of $1,606,800.00.

Moderna Stock Down 2.0 %

MRNA stock opened at $118.75 on Friday. The company has a 50 day moving average price of $134.13 and a two-hundred day moving average price of $111.96. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The stock has a market capitalization of $45.51 billion, a P/E ratio of -7.58 and a beta of 1.54. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same quarter in the previous year, the business earned $0.19 earnings per share. The business’s revenue for the quarter was down 91.0% on a year-over-year basis. As a group, sell-side analysts expect that Moderna, Inc. will post -7.46 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on MRNA. William Blair reissued a “market perform” rating on shares of Moderna in a report on Thursday. Canaccord Genuity Group upped their price target on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. Royal Bank of Canada lifted their price objective on Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a report on Monday, June 3rd. UBS Group upped their target price on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $214.00 price target on shares of Moderna in a research note on Thursday. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $134.02.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. LPL Financial LLC raised its position in shares of Moderna by 7.2% in the 3rd quarter. LPL Financial LLC now owns 115,782 shares of the company’s stock worth $11,959,000 after buying an additional 7,811 shares during the period. Mariner LLC lifted its stake in shares of Moderna by 5.2% in the 3rd quarter. Mariner LLC now owns 20,242 shares of the company’s stock valued at $2,091,000 after purchasing an additional 996 shares in the last quarter. Stifel Financial Corp grew its holdings in shares of Moderna by 19.0% during the 3rd quarter. Stifel Financial Corp now owns 75,871 shares of the company’s stock worth $7,837,000 after purchasing an additional 12,099 shares during the period. Natixis Advisors L.P. increased its position in Moderna by 19.9% during the 3rd quarter. Natixis Advisors L.P. now owns 19,924 shares of the company’s stock worth $2,058,000 after purchasing an additional 3,310 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC increased its position in Moderna by 34.0% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 7,664 shares of the company’s stock worth $792,000 after purchasing an additional 1,945 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.